Press release
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will attend and present at the following investor conferences: Cantor Fitzgerald 2025 Annual Global Healthcare Conference Location: New York, NY, U.S.Date: September 4, 2025Time: 1:35-2:05 PM ETType: Fireside chatPresenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early DevelopmentWebcast: Link H.C. Wainwright 27th Annual Global Investment Conference Location: New York, NY, U.S.Date: September 9, 2025Time: 2:00-2:30 PM ETType: Company presentation Presenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early DevelopmentWebcast: Link Fulcrum management will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Following the events, webcast replay links will be posted to Fulcrum Therapeutics Investor Relations’ Events and Presentations page. About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn. About PociredirPociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment o...